The Food and Drug Administration has approved Piqray (alpelisib) tablets to treat men and postmenopausal women whose advanced breast cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative and PIK3CA-mutated.
Piqray is to be used in combination with the FDA-approved endocrine therapy fulvestrant. Theย PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) is indicated following progression on or after an endocrine-based regimen.
Continue reading “FDA approves new drug to treat advanced breast cancer”